The effect of salbutamol on pulmonary volumes and capacities

Comparison the effect of salbutamol via nebulizer, spray with and without spacer on pulmonary function in Chronic Obstructive Pulmonary Disease (COPD)

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

IRCT

Registry ID

IRCT20200228046634N1

Enrollment

Registered

2021-05-15

Start date

2020-05-21

Completion date

Unknown

Last updated

2021-05-26

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Chronic Obstructive Pulmonary Disease (COPD). Chronic obstructive pulmonary disease, unspecified

Interventions

Intervention 1: The intervention group: receiving 200 micro grams of Salbutamol Equivalent to 2 puffs via Salbutamol spray under the Ventalex brand two minutes apart at a time. Intervention 2: The i

Eligibility

Sex/Gender

All

Age

40 Years to 75 Years

Inclusion criteria

Inclusion criteria: Satisfaction to participate in research Abnormal spirometry test including 0.7= FEV1/FVC ratio Age of 40-75 years old Physical ability to perform spirometry maneuvers Lack of pregnancy With body mass index between 18.5 - 25 Stages 1-4 of the disease based on GOLD criteria No specific intervention related to COPD or other possible diseases other than routine treatments Having awareness, the power of speech and communication Having a stable physiological state to answer questions No spirometry contraindications (uncontrolled blood pressure, infectious respiratory infection, active hemoptysis, recent eye or ear surgery, rupture of the tympanic membrane, recent history of CVA or pulmonary embolism, history of myocardial infarction or unstable angina in the last 6 weeks)

Exclusion criteria

Exclusion criteria: Severely ill patients with COPD exacerbation with loss of consciousness or need for intubation Patients with comorbidity disorders such as heart failure, kidney, liver and diabetes Asthma, pneumonia and severe respiratory failure with cyanosis and confusion

Design outcomes

Primary

Measure	Time frame
The pulmonary volumes and capacities. Timepoint: The Measurement of pulmonary volumes and capacities at the beginning of the study and 15, 30, 60 and 90 minutes after the beginning of the intervention. Method of measurement: Perform the spirometry test in two consecutive days.;The respiratory indicators. Timepoint: At the beginning of the study and 15, 30, 60 and 90 minutes after the beginning of the intervention. Method of measurement: The Respiratory Rate by counting the number of chest ups and downs and the percentage of oxygen saturation of the blood using the pulseoximetry device.	—

Measure

Time frame

The pulmonary volumes and capacities. Timepoint: The Measurement of pulmonary volumes and capacities at the beginning of the study and 15, 30, 60 and 90 minutes after the beginning of the intervention. Method of measurement: Perform the spirometry test in two consecutive days.;The respiratory indicators. Timepoint: At the beginning of the study and 15, 30, 60 and 90 minutes after the beginning of the intervention. Method of measurement: The Respiratory Rate by counting the number of chest ups and downs and the percentage of oxygen saturation of the blood using the pulseoximetry device.

—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactMaryam Derogar

Gonabad University of Medical Sciences

dm.derogar72@gmail.com+98 56 3249 6362

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026